apl. Prof. Dr. Robert Stöhr

Medizinische Fakultät

FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment? (2020) van Rhijn BW, Mertens LS, Mayr R, Bostrom PJ, Real FX, Zwarthoff EC, Boormans JL, et al. Journal article Malignant teratoid tumor of the thyroid gland: an aggressive primitive multiphenotypic malignancy showing organotypical elements and frequent DICER1 alterations—is the term “thyroblastoma” more appropriate? (2020) Agaimy A, Witkowski L, Stöhr R, Cuenca JCC, González-Muller CA, Brütting A, Bährle M, et al. Journal article YAP1-MAML2-Rearranged Poroid Squamous Cell Carcinoma (Squamoid Porocarcinoma) Presenting as a Primary Parotid Gland Tumor (2020) Agaimy A, Stöhr R, Tögel L, Hartmann A, Cramer T Journal article Molecular Composition of Genomic TMPRSS2-ERG Rearrangements in Prostate Cancer (2019) Krumbholz M, Agaimy A, Stöhr R, Burger M, Wach S, Taubert H, Wullich B, et al. Journal article Expression of GP88 (Progranulin) Protein Is an Independent Prognostic Factor in Prostate Cancer Patients (2019) Abdulrahman A, Eckstein M, Jung R, Guzman J, Weigelt K, Serrero G, Yue B, et al. Journal article Distinct genetic alterations and luminal molecular subtype in nested variant of urothelial carcinoma (2019) Weyerer V, Weisser R, Moskalev E, Haller F, Stöhr R, Eckstein M, Zinnall U, et al. Journal article Efficacy of anti-PD(L)1 treatment in patients with metastatic urothelial cancer based on mRNA- and protein- based PD-L1 determination: Results from the multicentric, retrospective FOsMIC trial (2019) Jarczyk J, Wirtz R, Roghmann F, Juette H, Kriegmair MC, Worst TS, Sikic D, et al. Conference contribution Prognostic role of FGFR Mutations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second-line setting (2019) Roghmann F, Wirtz R, Jarczyk J, Kriegmair MC, Worst TS, Sikic D, Wach S, et al. Conference contribution Evaluation of different diagnostic methods for identification of FGFR alteration in advanced urothelial carcinomas: Proficiency results based on multiple RNA extraction kits and mutation detection methods (2019) Weyerer V, Stöhr R, Juette H, Wirtz R, Eckstein M, Roghmann F, Breyer J, et al. Conference contribution Comparative analysis of tumour mutational burden (TMB) prediction methods and its association with determinants of the tumour immune microenvironment of urothelial bladder cancer (UBC) (2019) Eckstein M, Hartmann A, Strissel P, Strick R, Wach S, Taubert H, Wullich B, et al. Conference contribution